An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

We have previously reported the aqueous phase synthesis of mono-dispersive Fe3O4 nanoparticles with amine group surface modification. The nanoparticles exhibit satisfactory biocompatibility and significant MRI contrast in both in vitro and in vivo models. The magnetite nanoparticles could be manipulated by externally applied magnetic field. In this study, we have modified the naoparticle as an anti-cancer chemotherapeutic agent that capable of magnetic field guided targeting while traceable by MRI. We evaluate the anti-cancer drug epirubicin loading capacity and efficiency by spectrophotometric measurement. The epirubicin loaded onto the nanoparticles was proportional to the added substrate and a typical loading efficiency is close to 100 % at lower concentration that reached a plateau at 0.2% initial drug concentration for 2μM of nanoparticle in 1mL reaction volume. We than evaluated the anticancer efficacy of the epirubicin loaded nanoparticle complex using a drug resistant cell line MBT-2. An improved cytotoxicity of to the cancer cell line was revealed by WST-1 assay for the drug loaded nanoparticle compared to free drugs of the same dosage. A dosage dependent cancer cell cytotoxicty was noticed in the test dosage range for the drug loaded on the nanoparticles but not in the free drug groups. In conclusion, the current study demonstrated a magnetite nanoparticle served as an alternative anti-cancer drug carrier. In addition to its magnetic force manipulation and MRI contrast property, the magnetite carrier was able to overcome drug resistance of cancer cells and obtained an improved in vitro chemotherapeutic efficacy. Future works to explore the possible molecular and cellular mechanisms behind its anti-drug resistance as well as in vivo animal model validation is warranted.

Original languageEnglish
Title of host publication2008 8th IEEE Conference on Nanotechnology, IEEE-NANO
Number of pages1
DOIs
Publication statusPublished - 2008 Nov 10
Event2008 8th IEEE Conference on Nanotechnology, IEEE-NANO - Arlington, TX, United States
Duration: 2008 Aug 182008 Aug 21

Publication series

Name2008 8th IEEE Conference on Nanotechnology, IEEE-NANO

Other

Other2008 8th IEEE Conference on Nanotechnology, IEEE-NANO
CountryUnited States
CityArlington, TX
Period08-08-1808-08-21

Fingerprint

Chemotherapy
Iron oxides
Nanoparticles
Cells
Magnetic resonance imaging
Magnetite nanoparticles
Magnetic fields
Magnetite
Cytotoxicity
Biocompatibility
Surface treatment
Amines
Assays
Animals
Substrates

All Science Journal Classification (ASJC) codes

  • Electrical and Electronic Engineering

Cite this

Wu, P. C., Tsai, T. L., Cheng, F. Y., Yeh, C. S., & Shieh, D. B. (2008). An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line. In 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO [4617247] (2008 8th IEEE Conference on Nanotechnology, IEEE-NANO). https://doi.org/10.1109/NANO.2008.265
Wu, Ping Chin ; Tsai, Tsung Lin ; Cheng, Fong Yu ; Yeh, Chen Sheng ; Shieh, Dar Bin. / An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line. 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO. 2008. (2008 8th IEEE Conference on Nanotechnology, IEEE-NANO).
@inproceedings{63e67cb21dfc47b98e993a4cef5e8bdc,
title = "An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line",
abstract = "We have previously reported the aqueous phase synthesis of mono-dispersive Fe3O4 nanoparticles with amine group surface modification. The nanoparticles exhibit satisfactory biocompatibility and significant MRI contrast in both in vitro and in vivo models. The magnetite nanoparticles could be manipulated by externally applied magnetic field. In this study, we have modified the naoparticle as an anti-cancer chemotherapeutic agent that capable of magnetic field guided targeting while traceable by MRI. We evaluate the anti-cancer drug epirubicin loading capacity and efficiency by spectrophotometric measurement. The epirubicin loaded onto the nanoparticles was proportional to the added substrate and a typical loading efficiency is close to 100 {\%} at lower concentration that reached a plateau at 0.2{\%} initial drug concentration for 2μM of nanoparticle in 1mL reaction volume. We than evaluated the anticancer efficacy of the epirubicin loaded nanoparticle complex using a drug resistant cell line MBT-2. An improved cytotoxicity of to the cancer cell line was revealed by WST-1 assay for the drug loaded nanoparticle compared to free drugs of the same dosage. A dosage dependent cancer cell cytotoxicty was noticed in the test dosage range for the drug loaded on the nanoparticles but not in the free drug groups. In conclusion, the current study demonstrated a magnetite nanoparticle served as an alternative anti-cancer drug carrier. In addition to its magnetic force manipulation and MRI contrast property, the magnetite carrier was able to overcome drug resistance of cancer cells and obtained an improved in vitro chemotherapeutic efficacy. Future works to explore the possible molecular and cellular mechanisms behind its anti-drug resistance as well as in vivo animal model validation is warranted.",
author = "Wu, {Ping Chin} and Tsai, {Tsung Lin} and Cheng, {Fong Yu} and Yeh, {Chen Sheng} and Shieh, {Dar Bin}",
year = "2008",
month = "11",
day = "10",
doi = "10.1109/NANO.2008.265",
language = "English",
isbn = "9781424421046",
series = "2008 8th IEEE Conference on Nanotechnology, IEEE-NANO",
booktitle = "2008 8th IEEE Conference on Nanotechnology, IEEE-NANO",

}

Wu, PC, Tsai, TL, Cheng, FY, Yeh, CS & Shieh, DB 2008, An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line. in 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO., 4617247, 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO, 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO, Arlington, TX, United States, 08-08-18. https://doi.org/10.1109/NANO.2008.265

An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line. / Wu, Ping Chin; Tsai, Tsung Lin; Cheng, Fong Yu; Yeh, Chen Sheng; Shieh, Dar Bin.

2008 8th IEEE Conference on Nanotechnology, IEEE-NANO. 2008. 4617247 (2008 8th IEEE Conference on Nanotechnology, IEEE-NANO).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line

AU - Wu, Ping Chin

AU - Tsai, Tsung Lin

AU - Cheng, Fong Yu

AU - Yeh, Chen Sheng

AU - Shieh, Dar Bin

PY - 2008/11/10

Y1 - 2008/11/10

N2 - We have previously reported the aqueous phase synthesis of mono-dispersive Fe3O4 nanoparticles with amine group surface modification. The nanoparticles exhibit satisfactory biocompatibility and significant MRI contrast in both in vitro and in vivo models. The magnetite nanoparticles could be manipulated by externally applied magnetic field. In this study, we have modified the naoparticle as an anti-cancer chemotherapeutic agent that capable of magnetic field guided targeting while traceable by MRI. We evaluate the anti-cancer drug epirubicin loading capacity and efficiency by spectrophotometric measurement. The epirubicin loaded onto the nanoparticles was proportional to the added substrate and a typical loading efficiency is close to 100 % at lower concentration that reached a plateau at 0.2% initial drug concentration for 2μM of nanoparticle in 1mL reaction volume. We than evaluated the anticancer efficacy of the epirubicin loaded nanoparticle complex using a drug resistant cell line MBT-2. An improved cytotoxicity of to the cancer cell line was revealed by WST-1 assay for the drug loaded nanoparticle compared to free drugs of the same dosage. A dosage dependent cancer cell cytotoxicty was noticed in the test dosage range for the drug loaded on the nanoparticles but not in the free drug groups. In conclusion, the current study demonstrated a magnetite nanoparticle served as an alternative anti-cancer drug carrier. In addition to its magnetic force manipulation and MRI contrast property, the magnetite carrier was able to overcome drug resistance of cancer cells and obtained an improved in vitro chemotherapeutic efficacy. Future works to explore the possible molecular and cellular mechanisms behind its anti-drug resistance as well as in vivo animal model validation is warranted.

AB - We have previously reported the aqueous phase synthesis of mono-dispersive Fe3O4 nanoparticles with amine group surface modification. The nanoparticles exhibit satisfactory biocompatibility and significant MRI contrast in both in vitro and in vivo models. The magnetite nanoparticles could be manipulated by externally applied magnetic field. In this study, we have modified the naoparticle as an anti-cancer chemotherapeutic agent that capable of magnetic field guided targeting while traceable by MRI. We evaluate the anti-cancer drug epirubicin loading capacity and efficiency by spectrophotometric measurement. The epirubicin loaded onto the nanoparticles was proportional to the added substrate and a typical loading efficiency is close to 100 % at lower concentration that reached a plateau at 0.2% initial drug concentration for 2μM of nanoparticle in 1mL reaction volume. We than evaluated the anticancer efficacy of the epirubicin loaded nanoparticle complex using a drug resistant cell line MBT-2. An improved cytotoxicity of to the cancer cell line was revealed by WST-1 assay for the drug loaded nanoparticle compared to free drugs of the same dosage. A dosage dependent cancer cell cytotoxicty was noticed in the test dosage range for the drug loaded on the nanoparticles but not in the free drug groups. In conclusion, the current study demonstrated a magnetite nanoparticle served as an alternative anti-cancer drug carrier. In addition to its magnetic force manipulation and MRI contrast property, the magnetite carrier was able to overcome drug resistance of cancer cells and obtained an improved in vitro chemotherapeutic efficacy. Future works to explore the possible molecular and cellular mechanisms behind its anti-drug resistance as well as in vivo animal model validation is warranted.

UR - http://www.scopus.com/inward/record.url?scp=55349112886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349112886&partnerID=8YFLogxK

U2 - 10.1109/NANO.2008.265

DO - 10.1109/NANO.2008.265

M3 - Conference contribution

AN - SCOPUS:55349112886

SN - 9781424421046

T3 - 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO

BT - 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO

ER -

Wu PC, Tsai TL, Cheng FY, Yeh CS, Shieh DB. An iron oxide nanoparticle drug carrier for improved cancer chemotherapy in drug resistance line. In 2008 8th IEEE Conference on Nanotechnology, IEEE-NANO. 2008. 4617247. (2008 8th IEEE Conference on Nanotechnology, IEEE-NANO). https://doi.org/10.1109/NANO.2008.265